Condition
Solid Tumor|Lymphoma
Estimated Enrollment: 121
Age Group: 18 Years and older (Adult, Senior)
Gender: All
Study Type: Interventional
Study Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment
Study ID Numbers: PXD101-CLN-9
Study First Received: December 18, 2006
Last Updated: July 7, 2015
Estimated Primary Completion Date: August 2011
Primary Outcome Measures:
Safety, tolerability and maximum tolerated dose of orally administered PXD101 for each cohort|Determine the pharmacokinetics of oral PXD101 when dosed once or twice daily at various dose levels|Explore anti-tumor activity|Determine the safety, tolerability, and anti-tumor activity of orally administered PXD101 to patients with lymphoma
Sponsors and Collaborators:
Onxeo|Spectrum Pharmaceuticals, Inc
Website Link: https://ClinicalTrials.gov/show/NCT00413075
